Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related HAE
Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug
Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Analysts at Benchmark downgraded Haemonetics (NYSE: HAE) from “buy” to “hold.” The target price for Haemonetics has been lowered from $49 to $46. Haemonetics shares closed at $42.54 yesterday.

Hilliard Lyons downgraded Franklin Electric Co (NASDAQ: FELE) from “buy” to “neutral.” Franklin Electric's shares closed at $45.42 yesterday.

Latest Ratings for HAE

Jun 2018JefferiesMaintainsBuyBuy
May 2018Morgan StanleyMaintainsOverweightOverweight
Feb 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for HAE
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (FELE + HAE)

View Comments and Join the Discussion!